Michael Gelband’s Vera Therapeutics VERA Stock Holding History

Michael Gelband’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$480K	Sell	11,191 -306,160	-96%	-$11.4M	﹤0.01%	1253
2026 Q1	$12.8M	Buy	317,351 +244,610	+336%	+$10.5M	0.1%	182
2025 Q4	$3.68M	Buy	+72,741	New	+$2.58M	0.03%	581
2025 Q3	–	Sell	-20,108	Closed	-$474K	–	2056
2025 Q2	$474K	Sell	20,108 -51,452	-72%	-$1.16M	﹤0.01%	1166
2025 Q1	$1.72M	Buy	+71,560	New	+$2.3M	0.02%	747
2024 Q4	–	Sell	-153,596	Closed	-$6.79M	–	2096
2024 Q3	$6.79M	Buy	153,596 +111,679	+266%	+$4.24M	0.04%	312
2024 Q2	$1.52M	Buy	+41,917	New	+$1.66M	0.01%	878
2024 Q1	–	Sell	-28,005	Closed	-$431K	–	1986
2023 Q4	$431K	Buy	+28,005	New	+$356K	﹤0.01%	1072
2021 Q3	–	Sell	-12,841	Closed	-$170K	–	2669
2021 Q2	$170K	Buy	+12,841	New	+$200K	﹤0.01%	2034

Other funds holding VERA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Michael Gelband's VERA Position: Q2 2026 in Review

Michael Gelband reduced its Vera Therapeutics (VERA) stake by 96% in Q2 2026, selling an estimated $11.4M and leaving 11,191 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Michael Gelband first reported a position in VERA in Q2 2021 and has held it in 9 quarters since. The position peaked at $12.8M in Q1 2026. 218 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

Michael Gelband held 11,191 shares of Vera Therapeutics worth $480K as of Q2 2026.
Michael Gelband sold 306,160 Vera Therapeutics shares in Q2 2026, an estimated $11.4M.
Vera Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1253 holding.
Michael Gelband first reported a position in Vera Therapeutics in Q2 2021 and has held it in 9 quarters since.
Michael Gelband's Vera Therapeutics position peaked at $12.8M in Q1 2026.
218 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.